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DESIGN OF FLOW CYTOMETRY PANELS TO INVESTIGATE KILLER 
IMMUNOGLOBULIN-LIKE RECEPTOR EXPRESSING LYMPHOCYTES IN 
ANKYLOSING SPONDYLITIS 
 
 
JOHN S. LEE 
 
ABSTRACT 
 The major histocompatibility complex (MHC) class I molecule, Human 
Leukocyte Antigen B27 (HLA-B27) is a strong genetic risk factor for Ankylosing 
Spondylitis (AS).  However, the mechanism linking HLA-B27 and the 
development of AS is unknown.  Recent studies have shown that monoclonal 
antibodies targeting interleukin 17A (IL-17A) are an effective therapy for many 
patients with AS suggesting that IL-17A secreting lymphocytes mediate the 
disease.  Published experimental evidence suggests further a potential role for 4 
specific killer cell immunoglobulin-like receptors (KIRs) in the pathogenesis of 
AS, namely KIR3DL1, KIR3DL2, KIR2DL5, and KIR3DS1.  KIRs are 
immunomodulatory receptors for MHC class I molecules that are expressed by a 
variety of lymphocyte subsets. We hypothesize that the expression of these AS-
associated KIRs differentially modulates the expression of IL-17A in HLA-B27 
positive vs. negative individuals thereby affecting susceptibility to AS.  To begin 
to address this hypothesis, the experiments described in thesis were performed 
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to develop a set of multi-color flow cytometry panels that permit the analysis of 
expression of KIR3DL1, KIR3DL2, KIR2DL5, KIR3DS1 and of IL-17A by major 
classical and unconventional lymphocytes subsets.  These panels will be used in 
future studies to analyze peripheral blood samples from genotyped HLA-B27 
positive and negative healthy individuals as well as from AS patients and 
controls.    
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INTRODUCTION 
 
Ankylosing spondylitis (AS) is a form of chronic arthritis, primarily affecting 
the sacroiliac joints and the spine.  AS usually affects younger male patients from 
15 to 30 years of age.  The cause of AS is largely unknown, but there is strong 
evidence that the gene HLA-B27 plays a direct role in increasing susceptibility to 
AS.1  Patients with AS suffer from severe back pain and stiffness, in particular in 
the morning.  Moreover, many AS patients develop deformities in their back due 
to the fusion of vertebrae. Over time, this causes a hunched back and affects the 
mobility of the individual.  The ankylosed spine is also prone to fracture. 
In addition, this disease has been known to cause inflammation in the 
peripheral joints, eyes and promote new bone formation in affected areas. 
Unfortunately, there is no cure for this disease but there have been treatments 
that target specific inflammatory cytokines to reduce pain and inflammation.2  
Between 0.1% to 1.8% of people are affected, making it as common as 
rheumatoid arthritis.1 
 
HLA-B27 and its Association with AS 
HLA-B27 is one of the many Major Histocompatibility Complex (MHC) 
Class I molecules that is responsible for presenting endogenous peptides to 
lymphocytes, specifically to CD8+ cytotoxic T-cells. Structurally, the MHC class I 
heavy chains form a heterotrimeric complex with β2-microglobulin (β2m) and a 
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short peptide of 8-10 amino acids.  This complex is generated inside of the 
endoplasmic reticulum (ER). Once this complex is fully assembled, it is 
transported to the cell surface, where it is then recognized by other cells.2  
In the early 1970s, serological procedures that were initially used for 
tissue typing organ transplantations were adopted in rheumatological research.  
This led to the discovery of the association between HLA-B27 and AS.3  HLA-B27 
was the first HLA allele that was found to have an association with an 
inflammatory disease and was also shown to be associated with other 
spondyloarthropathies like reactive arthritis, psoriatic arthritis, and uveitis.4  
Almost 90% of people with AS are HLA-B27 positive.5 Although the association 
between HLA-B27 and AS is very strong, the presence of HLA-B27 alone is not 
sufficient to induce disease. 
 
Hypotheses for the Association between HLA-B27 and AS 
There are currently four major hypotheses that attempt to explain the 
association between HLA-B27 and AS. 
1) Arthritogenic/spondylitogenic peptide hypothesis: This hypothesis 
refers to the well-established MHC class I function of HLA-B27, which is 
antigen presentation to CD8+ T cells.  It is postulated that activation of 
cytotoxic CD8+ T-cells and subsequent cell-mediated immune responses 
against specific HLA-B27/peptide combinations lead to disease.6   
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2) Misfolding hypothesis: HLA-B27 has a unique property in that HLA-B27 
heavy chains have a tendency to misfold during assembly of the 
heterotrimeric complex of the HLA-B27 heavy chain, β2m, and peptide in 
the ER.  Accumulation of these misfolded proteins within the ER has been 
demonstrated to illicit a cellular stress response known as unfolded protein 
response (UPR), which comprises a number of pathways, all involved in 
decreasing the amount of misfolded protein aggregation within in the ER.  
Activation of the UPR can also lead to inflammation.7   
3) Homodimer/NK cell receptor hypothesis:  Another unique property of 
HLA-B27 is that HLA-B27 molecules may form disulfide linked 
homodimers, which do not need the presence of β2m or peptide for 
expression on the cell surface.  After this discovery, it was found that 
KIR3DL2, an inhibitory NK cell receptor, displayed a stronger affinity for 
the aforementioned HLA-B27 heavy chain homodimer than for regular 
HLA-B27 complexes.  Interestingly, NK cell receptors like KIR3DL2 are 
not exclusively expressed on NK cells.  It has been shown that HLA-B27 
heavy chain homodimers may induce the inappropriate activation of CD4+ 
T-cells expressing KIR3DL2.2   
4) Microbial hypotheses: The results from multiple studies implicate 
microbes in the pathogenesis of AS and other HLA-B27 associated 
diseases.  These lines of evidence include the induction of reactive 
arthritis by certain Gram-negative bacteria, the high prevalence of 
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intestinal inflammation in patients with AS, and the importance of 
microbiota for the development of arthritis in HLA-B27 transgenic rats.  
Microbial hypotheses to explain the association of HLA-B27 and AS 
invoke immunological cross-reactivity, compromised immunological 
defenses against certain microbes in HLA-B27+ individuals, or indirect 
consequences involving intestinal microbiota.8 
Each of the 4 hypotheses has its strengths and weaknesses and, despite 
extensive research efforts, the exact mechanism linking HLA-B27 and AS is still 
unknown. 
 
Killer Cell Immunoglobulin-like Receptors 
 Killer cell immunoglobulin-like receptors are a family of type I 
transmembrane proteins that are expressed on the surface of NK cells and other 
types of lymphocytes.9  They are referred to as immunoglobulin-like because they 
share structural similarities with antibody molecules.  KIRs can act as both 
activators and inhibitors of NK cell cytotoxicity through their interaction with MHC 
class I molecules expressed on the surface of nucleated cells.10  The function of 
KIRs on other lymphocytes is well understood. 
Inhibitory KIRs have cytoplasmic tails with immunoreceptor tyrosine-based 
motifs (ITIM) that are phosphorylated when the receptors interact with MHC class 
I molecules.  ITIM phosphorylation induces the activation of cytoplasmic tyrosine 
phosphatases that remove phosphate groups from tyrosine residues of various 
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signaling molecules.  This prevents the activation of the KIR-expressing NK cell 
when the receptor interacts with self MHC molecules on healthy host cells.9   
 
 
Figure 1.  Activating and inhibitory killer cell immunoglobulin-like 
receptors.  A. Inhibitory KIRs recognize MHC class I molecules expressed on 
normal host cells and ensure that these host cells are not attacked. B. Activating 
KIRs detect the presence of ligands on aberrant cells, in which class I MHC 
expression is usually reduced. This leads to NK cell activation and cytolysis.  
(Taken from Abbas).9 
 
Activating KIRs detect ligands on the surface of abnormal cells and 
increase the cytotoxic activity of the KIR expressing NK cells.  Activating KIRs do 
not have ITIMs, instead, they have positively charged arginine or lysine residues 
in their transmembrane domains that facilitate interaction with other membrane 
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proteins that have cytoplasmic immunoreceptor tyrosine-based activation motifs 
(ITAM) thereby promoting cell activation.11  
KIRs are encoded by the highly polymorphic KIR locus on Chromosome 
19.  Both the number and identity of KIR genes and the nucleotide sequences of 
individual KIR genes may differ between subjects.  An additional source of 
heterogeneity is that KIRs are not uniformly expressed.  Each NK cell or other 
KIR positive lymphocyte expresses only a selection the KIRs encoded by the 
subject’s KIR genes.12   
 
HLA-B27 and KIRs 
Experimental evidence suggests a potential role for 4 KIRs in the 
pathogenesis of AS.  KIR3DL1 has been shown to specifically interact with HLA-
B27, an interaction that may be affected by the type of peptide bound to HLA-
B27.13  KIR3DL2 does not bind well to the HLA-B28/β2m/peptide complex.  
Instead, KIR3DL2 has been shown to recognize HLA-B27 homodimers.14   
As discussed above, homodimerization is a unique feature of the HLA-B27 
heavy chain, and inappropriate activation of KIR3DL2 positive lymphocytes has 
been proposed as a mechanism linking HLA-B27 positivity and disease.15  
Recent genetic studies have furthermore suggested a potential role for KIR3DS1 
and KIR2DL5 in the pathogenesis of AS.16  
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Figure 2.  IL-23 signaling leading to IL-17A production in various cell 
populations.  Signaling through the IL-23 receptor induces IL-17A production by 
multiple types of immune cells including γδ Cells, iNKT-Cells, CD3+ T-Cells, 
CD4+  T-Cells, and NK Cells.  (Taken from Smith).17  
 
IL-23/IL-17A Axis in AS 
Recent genome-wide association studies have demonstrated 
polymorphisms in several non-HLA genes to be associated with susceptibility to 
AS in Caucasian populations.18  In particular, polymorphisms in several genes 
involved in IL-23 receptor signaling were found to be associated with AS.19  IL-23 
receptors are expressed on many immune cell, including CD4+ T-cells, γδ T-
cells, and NK cells.  IL-23 receptor signaling induces the expression of IL-17A.17  
IL-17A then acts on other types of cells to promote inflammatory responses.  This 
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IL-23/IL-17A axis is thought to be important in the defense against microbes like 
bacteria, parasites, fungi, and viruses.20   
There is strong evidence that the IL-23/IL-17A cytokine axis plays a role in 
AS pathogenesis.  Serum levels of IL-17A are higher in patients with AS 
compared with healthy subjects.17  Moreover, IL-17A inhibition has been shown 
to be an effective treatment for ankylosing spondylitis.21   
 
Lymphocyte Subsets 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Lymphocyte hierarchy. Surface markers used to identify specific 
lymphocyte populations.22,23 
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Multiple types of lymphocytes have been shown to secrete IL-17A 
including CD4+ T-cells, CD8+ T-cells, γδ T-cells, NK cells, NK T-cells, and 
Mucosal Associated Invariant T-Cells (MAIT) cells.  CD4+ helper and CD8+ 
cytotoxic T-cells are white blood cells that play a particularly important role in the 
adaptive immune system.  CD4+ helper T-cells secrete cytokines that promote 
the phagocytic activity of macrophages, B-cell antibody class switching, and 
activation of CD8+ cytotoxic T-cells.24  CD4+ helper T-cells are activated through 
the interaction of their T-cell receptors with MHC class II molecules that are 
expressed on the surface of antigen presenting cells like B-cells, dendritic cells, 
and macrophages.25   
CD8+ cytotoxic T-cells are lymphocytes that are involved in killing 
infected, damaged, or cancerous cells by releasing cytotoxins in response to 
activation via the interaction of their T-cell receptors and antigens presented by 
MHC class I molecules.26   
Unlike the α and β chains of the classical T-cell receptor, γδ T-cells 
express a T-cell receptor that is composed of a γ chain and a δ chain.  γδ T-cells 
are found in relatively low numbers compared to other lymphocyte subsets in the 
skin, lungs, gut mucosa, and uterus and play a role in eliciting and carrying out 
immune responses.27  
Natural killer cells are part of the innate immune system.  While T-cells 
interact with MHC molecules displayed on the surface of infected cells, causing 
the release of cytokine and induction of cytolysis or apoptosis, NK cells are 
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unique in that they can provide cytotoxic responses in the absence of “self” 
markers displayed by MHC class I molecules, resulting in much more rapid 
recognition and immune reactions.28  NK T-cells are a heterogeneous family of 
immune cells that have characteristics of both NK cells and T-cells.  NK T-cells 
express the invariant TCRvα24jα18 and recognize lipids presented by CD1 
molecules.  The effector functions of these cells include the rapid activation of T-
cells, B-cells, NK cells, dendritic cells, and macrophages.29   
MAIT cells are an unconventional subset of T-cells that express the 
invariant TCRvα7.2.  MAIT cells recognize antigens presented by the non-
classical MHC class I molecule MR1 and have been reported to have the unique 
role in controlling bacterial and yeast infections.30   
 
Peripheral Blood Mononuclear Cells 
 Peripheral blood mononuclear cells (PBMC) is an umbrella term that 
includes lymphocytes, monocytes, and other cells with a single round nucleus.31  
In order to isolate PBMCs from whole blood, a technique called density gradient 
centrifugation is used.  Whole blood samples are overlayed onto ficoll, a 
hydrophilic polysaccharide medium that, after centrifugation, separates the blood 
into a plasma layer, a PBMC layer, a polymorphonuclear cell layer, and a red 
blood cell layer.  The PBMC layer can be isolated by pipetting the cells.32   
Phorbol 12-myristate 13-acetate and Ionomycin are used in conjunction to 
stimulate cytokine production by cells in vitro.  PMA/Ionomycin serve to act as an 
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artificial stimulus that mimics TCR activation.  PMA directly activates Protein 
Kinase C, a kinase downstream of ligand-receptor activation.  Ionomycin is a 
calcium ionophore that can raise intracellular levels of calcium to induce Nuclear 
factor of activated T-cells (NFAT) signaling, and consequently up-regulate gene 
transcription.33 
 
Flow Cytometry and Fluorescence 
 
Figure 4. Flow cytometer overview. Laser light hits individual cells and scatter 
through different filters and are detected by a set of fluorescent channels.  
(Taken from Semrock).34 
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Flow cytometry is used to identify subsets of cells within a heterogeneous 
population using different parameters like size, shape, and cell surface marker 
expression.  Key components of flow cytometers are the fluidics system, lasers, 
detectors to sense the light, and a computer system to organize data for analysis.   
Once a sample has been placed into the flow cytometer, the sample is 
taken in by the machine, mixed into a stream of sheath fluid and passed through 
a narrowing funnel that forces the cells into a single file line.  This stream of 
single cells passes through several laser beams resulting in the scattering of light 
in a fashion that is dependent on the properties of each individual cell.35   
The two main forms of scattered light are forward and side scatter.  The 
degree of forward scatter is proportional to the size of the cells and the degree of 
side scatter is proportional to the granularity of the cells.  By analyzing the 
forward and side scatter together, the researcher can divide the heterogeneous 
populations of cells into individual populations with varying sizes, shapes, and 
complexities.36   
Fluorescence is a property of certain molecules called fluorophores that 
allows them to absorb light of short wavelengths and emit light of longer 
wavelengths.  A flow cytometer can detect light emitted from excited fluorescent 
molecules like labeled antibodies.  Monoclonal antibodies conjugated to 
fluorescent dyes, are used to identify the presence of different subsets of cells 
within heterogeneous samples because of their high specificity to surface 
markers on individual cells.37  This high specificity coupled with laser induced 
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fluorophore excitation leads to the fluorescent signal that can then be detected 
and subsequently analyzed. The fluorophores are excited by a specific 
wavelength of laser light when the cells pass through the laser beams in the flow 
cytometer.38  After excitation, the light emitted by the fluorophore is directed along 
a path with emission filters that filter out a light of a specific wavelength to be 
detected by sensors.36  For example, a single 488 nm green laser that excites 
FITC and phycoerythrin (PE) was the laser used in the first two color flow 
cytometers.  
There are many different classes of fluorophores including organic small 
molecules, proteins, semiconductor nanocrystals, and organic polymers.  The 
diverse structures and chemical compositions of the different classes of 
fluorophores enable researchers to stain their samples with a variety of colors 
and identify many different markers at the same time.39  Tandem dyes are 
composed of two covalently bonded fluorescent molecules, one of which acts as 
an excitation donor and the other as an acceptor.  These fluorophores have the 
unique characteristics of having the excitation properties of the donor molecule 
and the emission properties of the acceptor molecule.  By substituting different 
donor and acceptor molecules, new fluorophores can be designed. 
More recently, the Brilliant Violet (BV) organic polymers have expanded 
the number of dyes that can be used in flow cytometry staining simultaneously.  
Unlike traditional UV-violet excitable dyes, the BV dyes are larger and have 
structural fluorescent repeats that act cooperatively to produce a stronger and 
   
14 
 
longer lasting signal similar to the strong staining of fluorophores like PE and 
allophycocyanin (APC).40   
The use of modern multicolor flow cytometers like the LSR Fortessa (BD 
Biosciences), that are equipped with 5 lasers (350 nm, 407 nm, 488 nm, 561 nm, 
633 nm), enables the analysis of up to 18 colors simultaneously.41 
 
Spectral Overlap and Compensation 
 Spectral overlap occurs when the fluorescence of a particular dye spills 
into more channels than the one that is expected to detect the dye’s 
fluorescence.42  For example, FITC is a dye that emits primarily a green light that 
is measured in the FITC channel.  FITC also emits a significant amount of yellow 
light, which is detected by the PE channel (Figure 5).  This spectral overlap issue 
is amplified significantly when working with more colors.  Fluorescence 
compensation is used to account for this spectral overlap.  Compensation is the 
mathematical correction of the fluorescence signal intensities by applying a 
compensation matrix, which is generated by analyzing beads stained with single 
dyes. Compensation ensures that the fluorescent signal detected by each 
channel comes from the fluorophore that is getting measured and corrects any 
potential false positive signal caused by spillover. 
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Figure 5. The problem of spectral overlap.  Due to spectral overlap, the light 
emitted by FITC will be detected not only in the FITC channel but also in the PE 
channel.  (Taken from Medical University of South Carolina).43  
 
Study Goals 
Therapy with monoclonal antibodies or other biologics, targeting TNF or 
IL-17A has been shown to be effective for many patients with AS.21  Potential 
downsides of these therapies is that they are very expensive and leave patients 
vulnerable to the dangers of chronic immunosuppression.44  As a result, there 
has been a greater emphasis on finding a cure and other preventative measures, 
both of which are unlikely to occur without a better grasp of the role HLA-B27 
plays in AS pathogenesis.  In this study, we wanted to design flow panels that 
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would allow the identification of the KIR repertoire on lymphocyte subsets and to 
see if there is a difference in the expression of these different lymphocyte 
subsets and their production of inflammatory cytokines. These studies in healthy 
individuals are critical prerequisites before analyzing specimen from patients who 
are HLA-B27+, HLA-B27-, and who have AS. 
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METHODS 
 
Subjects 
Blood samples were obtained from healthy volunteers and through the 
Crimson Cores program at Brigham and Women’s Hospital.  The Crimson 
Biomaterials Collection Core Facility collects discarded clinical blood samples 
and matches them to investigator-defined criteria.  These samples are fully 
anonymized and were needed to increase the experiment’s population size.  The 
Crimson blood samples were necessary because we were interested in 
differential KIR expression on lymphocytes of different subjects and we were able 
to get many blood samples for little cost. 
 
PBMC Isolation 
Freshly collected human blood samples were processed within two hours 
of collection.  10 mL of anticoagulated blood was diluted with 14 mL of Hanks 
Balanced Salt Solution (HBSS) without Ca/Mg.  We then added 15 mL of Ficoll-
Paque (GE Healthcare) density medium into the insert of a SepMate-50 
(STEMCELL Technologies) conical vial, overlayed the sample, and centrifuged at 
2200 rpm for 20 minutes at room temperature with the brakes turned on.  The 
PBMC layer was poured into a new 50 mL conical vial.  The sample was then 
centrifuged at 1300 rpm for 10 minutes at 4° C.  The resulting supernatant was 
aspirated and the cell pellet was resuspended and counted using Trypan Blue 
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(Life Technologies) cell viability dye and a Countess (Invitrogen) automated cell 
counter.  The sample was centrifuged again at 1200 rpm for 10 minutes and 
resuspended in a volume associated with the desired cell concentration.   
 
Cell Surface Staining  
Surface marker staining was performed in 96 well plates.  150 μL samples 
were put into wells of a 96-well round-bottom plate at a concentration of 2 x 106 
cells/150 μL.  The cells were first stained with eFluor 455 UV fixable viability dye 
(1:500, 150 μL per well) in HBSS for 15 minutes on ice.  The cells were then 
washed with staining buffer [HBSS with 2mM Ethylenediaminetetraacetic Acid  
(EDTA) and 0.5% Bovine Serum Albumin (BSA)] and resuspended in staining 
buffer with Fc block (Biolegend, 1:100, 75 μL per well) to inhibit non-specific 
binding of antibodies to Fc receptors on white blood cells.  After a 10 minute 
incubation on ice fluorescently labeled antibodies diluted in Brilliant buffer (BD 
Biosciences) were added.  The cells were incubated for 20 minutes on ice 
followed by two washes with staining buffer.  If analysis was delayed, the cells 
were fixed with IC Fixation Buffer (eBioscience) for 10 minutes at room 
temperature and stored in a 4° C refrigerator in the dark.  If the analysis occurred 
on the day of cell preparation, the cells were resuspended in 250 μL of staining 
buffer and analyzed.  A 5-laser, 20-parameter Fortessa flow cytometer (BD 
Biosciences) was used for data collection and FlowJo Software (FlowJo) was 
used for analysis.  
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Bead Compensation 
 On the day of analysis, UltraComp eBeads (eBioscience) were vortexed 
thoroughly in order to prevent sedimentation.  A bead master mix was then 
prepared by mixing 250 μL staining buffer to 10 μL UltraComp beads per 
fluorescent channel.  250 μL of the bead maser mix was then aliquoted into 
individual FACS tubes.  Antibodies were then added to the individual FACS tubes 
at a dilution of 1:500.  These FACS tubes were then kept in the dark until 
analysis. 
 
In vitro stimulation and intracellular staining.  
2x106 Human PBMCs were added to individual wells of 96 well round-
bottom plates in RPMI-C medium. Cells were placed in a 37° C incubator for 20 
minutes prior to stimulation.  Cells were stimulated with PMA/Ionomycin 
(eBioscience).  Golgi Stop (BD Bioscience) was added to inhibit vesicle transport 
of cytokines.  After four hours of incubation at 37° C, cells were harvested and 
stained for surface markers as described.  After washing with staining buffer, the 
cells were fixed with IC Fixation Buffer (eBioscience) for 10 minutes at room 
temperature.  After three washes with permeabilization buffer (eBioscience), anti-
IL-17A antibody diluted in permeabilization buffer, was added for intracellular 
staining for another 30 minutes.  This was followed by a series of washes with 
permeabilization buffer.  The cells were then resuspended in staining buffer and 
analyzed. 
   
20 
 
Table 1. Antibody List. 
Dye Target Name Clone Company 
BV421 TCRvα24jα18 6B11 Biolegend 
  CCR7 G043H7 Biolegend 
BV510 CD4 OKT4 Biolegend 
  IL-17A BL168 Biolegend 
BV605 TCRvα7.2 3C10 Biolegend 
  HLA-DR L243 Biolegend 
BV650 CD16 3G8 Biolegend 
  IFNγ 4S.B3 Biolegend 
  CD38 HB7 Biolegend 
BV711 CD8a RPA-T8 Biolegend 
BV786 CD161 HP-3G10 Biolegend 
  CD45RA HI100 Biolegend 
FITC γδ TCR B1 Biolegend 
  CD4 RPA-T4 Biolegend 
PerCP-Cy5.5 KIR3DL1 - CD158e DX9 Biolegend 
PE KIR3DL1/DL2 - CD158e/k 5.133 Miltenyi 
PE-Dazzle CCR6 G034E3 Biolegend 
  γδ TCR B1 Biolegend 
PE-Cy5 CD19 HIB19 Biolegend 
PE-Cy7 CD56 5.1H11 Biolegend 
APC KIR3DL1/DS1 - CD158e1/2 REA168 Miltenyi 
Alexa Fluor 700 CD3 UCHT1 Biolegend 
APC-Cy7 KIR2DL5 - CD158f UP-R1 Miltenyi 
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RESULTS 
 
 
Compensation of Spectral Overlap 
Proper compensation is critical in high-dimensional fluorescent flow 
cytometry experiments.  In order to correct and compensate for potential spillover 
errors, UltraComp eBeads were stained with individual conjugated antibodies 
and used as single-color compensation controls.  The beads are around 6 μm in 
diameter, which is similar in size to that of PBMCs and permits their detection in 
the flow cytometer.  Half of the beads are coated with anti-Fc antibodies that 
capture fluorescently labeled antibodies upon incubation.  The other half is 
uncoated, providing a negative control in the same tube.  In Figure 6A, the 
emission signals from single stained beads are compared to the 
autofluorescence control of unstained beads in order to generate a compensation 
matrix that is then applied to data obtained from cells stained with multiple 
antibodies.  The plots in Figure 6B demonstrate how application of the 
compensation matrix corrects for fluorescent spillover resulting in the correct 
identification of CD3+CD19- T-cells and CD3-CD19+ B-cells. 
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A. 
 
B.          Before Compensation         After Compensation 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Bead Compensation.  A. The Alexa Fluor 350 panel consists of cells 
stained with FVD while the rest of the panels represent a subset of the single 
stained controls using UltraComp beads stained with individual conjugated 
antibodies.  B. The same PBMC specimen before and after application of the 
compensation matrix. 
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Flow Cytometry Panel Optimization Using Antibody Titration 
 Antibody concentrations need to be titrated to determine the minimum 
concentration of antibody needed to elicit a desired signal and thus maximize the 
economical use of the antibody resource.  By carefully identifying the optimal 
concentration of antibody and documenting it within our panel, we can assure 
that our experimental procedures will be consistent and reproducible and will 
conserve antibody quantity, which allows us to run more experiments. 
 An antibody cocktail with a starting dilution of 1:100 for each antibody was 
made and 1:2 serial dilutions were performed to produce antibody cocktails of 
1:100, 1:200, 1:400, and 1:800 dilutions.  2 x 106 PBMCs were then stained with 
the serially diluted antibody cocktails and analyzed.  After graphing compensated 
data as shown in Figure 7, we determined the optimal dilution of antibody by 
comparing the signal strength to the dilution of antibody used.  We chose the 
smallest antibody dilutions that displayed clear separation of populations, and 
included them into our flow panel.  
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Figure 7.  Antibody titration and corresponding fluorescence signal 
strength.   
 
 
1:100 
1:200 
1:400 
1:800 
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Cell Surface Panel 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2A.  Finalized flow panels for cell surface marker staining. 
 
Laser Channel  Marker Clone Company Dilution  
350 nm BUV395 Viability       
407 nm BV421 TCRvα24jα18 6B11 Biolegend 1:100 
  BV510 CD4 OKT4 Biolegend 1:500 
  BV605 TCRvα7.2 3C10 Biolegend 1:100 
  BV650 CD16 3G8 Biolegend 1:200 
  BV711 CD8a RPA-T8 Biolegend 1:500 
  BV786 CD161 HP-3G10  Biolegend 1:100 
488 nm FITC γδ TCR B1 Biolegend 1:100 
  PerCP-Cy5.5 KIR3DL1 DX9 Biolegend 1:100 
561 nm PE KIR3DL1/DL2 5.133 Miltenyi 1:20 
  PE-Dazzle CCR6 G034E3 Biolegend 1:100 
  PE-Cy5 CD19 HIB19 Biolegend 1:500 
  PE-Cy7 CD56 5.1H11 Biolegend 1:200 
633 nm APC KIR3DL1/DS1 REA168 Miltenyi 1:50 
  Alexa 700 CD3 UCHT1 Biolegend 1:100 
  APC-Cy7 KIR2DL5 UP-R1 Miltenyi 1:20 
 
 
      
Laser Channel  Marker Clone Company Dilution  
350 nm BUV395 Viability       
407 nm BV421 CCR7 G043H7 Biolegend 1:100 
  BV510 CD4 OKT4 Biolegend 1:500 
  BV605 HLA-DR L243 Biolegend 1:200 
  BV650 CD38 HB7 Biolegend 1:100 
  BV711 CD8a RPA-T8 Biolegend 1:500 
  BV786 CD45RA HI100 Biolegend 1:200 
488 nm FITC γδ TCR B1 Biolegend 1:100 
  PerCP-Cy5.5 KIR3DL1 DX9 Biolegend 1:100 
561 nm PE KIR3DL1/DL2  5.133 Miltenyi 1:20 
  PE-Dazzle CCR6 G034E3 Biolegend 1:100 
  PE-Cy5 CD19 HIB19 Biolegend 1:500 
  PE-Cy7 CD56 5.1H11 Biolegend 1:200 
633 nm APC KIR3DL1/DS1 REA168 Miltenyi 1:50 
  Alexa 700 CD3 UCHT1 Biolegend 1:100 
  APC-Cy7 KIR2DL5 UP-R1 Miltenyi 1:20 
Cell Surface Panel 2 
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Table 3. Finalized flow panel for intracellular cytokines post-stimulation. 
Antibody titrations were carried out with all the antibodies in the experimental 
flow panel to determine the minimum concentration of antibody to be used in the 
experiments as shown in the dilution column. 
 
 
CD4 Downregulation 
 During the analysis of cytokine expression in different lymphocyte subsets, 
there was an issue with CD4 downregulation upon stimulation of lymphocytes 
with PMA/Ionomycin.  This downregulation made it impossible to distinguish the 
CD4+ lymphocytes from the CD4- when the cells were stained with anti-CD4 
BV510, the anti-CD4 antibody used in the extracellular marker panels (Figure 8). 
 
Laser Channel  Marker Clone Company Dilution  
350 nm BUV395 Viability    
407 nm BV421 CCR7 G043H7 Biolegend 1:100 
  BV510 IL-17A BL168 Biolegend 1:100 
  BV605 HLA-DR L243 Biolegend 1:200 
  BV650 IFNγ  4S.B3 Biolegend 1:100 
  BV711 CD8a RPA-T8 Biolegend 1:100 
  BV786 CD45RA HI100 Biolegend 1:200 
488 nm FITC CD4 RPA-T4 Biolegend 1:25 
  PerCP-Cy5.5 KIR3DL1 DX9 Biolegend 1:100 
561 nm PE KIR3DL1/DL2 5.133 Miltenyi 1:20 
  PE-Dazzle  γδ TCR B1 Biolegend 1:100 
  PE-Cy5 CD19 HIB19 Biolegend 1:500 
  PE-Cy7 CD56 5.1H11 Biolegend 1:200 
633 nm APC KIR3DL1/DS1 REA168 Miltenyi 1:50 
  Alexa 700 CD3 UCHT1 Biolegend 1:100 
  APC-Cy KIR2DL5 UP-R1 Miltenyi 1:20 
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Figure 8. Managing the Problem of CD4 Downregulation.  CD4 fluorescence 
signal in Brilliant Violet 510 (BV510) or fluorescein isothyocyanate (FITC) and the 
decrease in signal after PMA/Io stimulation.  The presence of IL-17A expressing 
cells demonstrates that the stimulation process was successful. 
 
 Increasing the concentration of BV510 antibody used could potentially 
have solved the problem, but due to the high cost of the Brilliant Violet dyes this 
was not a practical solution.  We therefore switched the CD4 marker to a different 
channel.  The anti-CD4 FITC antibody is generally a weaker fluorescent signal 
than its BV510 counterpart, but it is much cheaper and can be used at much 
Stimulated Unstimulated 
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higher concentrations.  By using high concentrations of the FITC antibody, the 
problem of CD4 downregulation was managed and the flow panel was updated.  
 
Identification of classic and unconventional lymphocyte subsets 
 The optimized panels were then applied to PBMCs from a healthy subject 
to establish the gating strategy to identify important lymphocytes subsets. After 
compensation, the data set was first cleaned up.  This was done by first gating in 
the lymphocyte population, removing doublet cells, and gating out non-viable or 
CD19+ B-cells (Figure 9A).  From here the NK Cells were identified by gating on 
CD3-CD56+ cells and the T-cells were identified by gating on CD3+ cells.  By 
looking at the CD3+ cells and gating on CD4+ cells, we can identify the helper T-
cells and by gating on CD8+ cells, we can identify the cytotoxic T-cells.  By 
looking at the cytotoxic and helper T-cells respectively, we can gate on 
CD45RA+ cells to identify the Naïve T-cells.  We can then look further at the 
CD45RA- gate and gate for the CCR7+ central memory T-cells and the CCR7- 
effector memory T-cells.  The unconventional subsets of T-cells can be identified 
using the same data cleanup strategy shown in Figure 9A.  From here, we can 
gate on the CD3+ cells and from within this gate, we can then gate on γδ TCR to 
identify the γδ T-cells and TCRvα24jα18 to identify the NK T-cells.  Finally, we 
can look at the γδ TCR- and TCRvα24jα18- cells and gate on the CD161+ and 
TCRvα7.2+ cells to identify the MAIT cells. 
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C. 
 
 
 
 
 
 
 
 
Figure 9. Gating strategy. A. Data cleanup of lymphocytes excluding cell 
doublets, nonviable cells, and B-cells B. Gating of classical lymphocyte subsets 
C. Gating of unconventional lymphocyte subsets. 
 
 
KIR expression on NK and non-NK cells 
 The identification of KIRs follows the same data cleanup steps described 
in Figure 9A in which cell doublets, CD19+, and non-viable cells are gated out.  
The next step is to gate for the specific cell subsets of interest as described in 
Figure 9B and 9C.  The final step involves gating on the different KIR markers to 
identify their expression on each of the lymphocyte subsets of interest.  By doing 
this, we were not only able to determine that there is differential KIR expression 
on different subsets of lymphocytes but also between the cells of different 
subjects as well (Figure 11). 
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Figure 10. The use of combinatorial staining to identify KIR3DL2+ cells.  
The KIR3DL2 APC antibody from R&D did not stain properly.  Therefore, we 
stained with anti-KIR3DL1/Dl2 and anti-KIR3DL1 to identify cells expressing 
KIR3DL2. 
 
In our efforts to interrogate the expression of the 4 KIRs we first attempted 
to use an R&D antibody specific for KIR3DL2 (Clone: FAB2878A), but the 
antibody failed to stain any cells.  By using the gating strategy in Figure 9 to 
identify NK cells and the data in Figure 10, we were able to identify KIR3DL2+ 
cells by using a combinatorial staining strategy.  This strategy utilizes an antibody 
(Clone: 5.133) that stains both KIR3DL1 and KIR3DL2 and second antibody 
(Clone DX9) that identifies KIR3DL1.  By plotting KIR3DL1/DL2 vs. KIR3DL1, we 
can identify the cells that are KIR3DL2+. 
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B. 
 
 
Figure 11. Variable KIR Expression on Different Lymphocyte Subsets. A. 
Differential expression of KIRs on CD4+ T-cells, CD8+ T-cells, and NK cells from 
4 different subjects. B. Frequency of KIR3DL1 and KIR2DL5 positive cells 
amongst CD4+ T-cells, CD8+ T-cells, and NK cells (% Expression).   
  
In sample 1 of Figure 11, we see that less than 0.1% of the CD4+ T-cells 
express KIR3DL1 or KIR2DL5.  We also see that 0.31% of the CD8+ T-cells 
express KIR3DL1, while around 6% of the NK cells expess KIR3DL1.  Less than 
0.1% of the 3 lymphocyte subsets are KIR2DL5+.  In sample 2, around 0.1% of 
the CD4+ and CD8+ T-cells express KIR2DL5.  There is no KIR3DL1 expression 
on these CD8+ T-Cells, but 0.54% of the CD8+ T-cells express KIR3DL1.  9.53% 
KIR2DL5 
KIR3DL1 
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of the NK cells express KIR3DL1 and 1.13% express KIR2DL5.  In sample 3, 
less than 0.1% of the CD4+ T-cells express the two KIRS, while 0.38% of the 
CD8+ T-cells express KIR2DL5.  18.3% of the NK cells express KIR3DL1, while 
2.29% of the NK cells express KIR2DL5.  In sample 4, less than 0.1% of the 
CD4+ T-cells express the 2 KIRs.  Amongst the CD8+ T-cells, 0.61% express 
KIR3DL1 and 0.2% express KIR2DL5.  26.9% of the NK cells express KIR3DL1, 
while there is no expression of KIR2DL5.  This data shows how variable the 
expression of KIRs are on the different subsets of lymphocytes and in between 
different subjects.  Data are summarized in Panel B for 8 healthy subjects. 
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DISCUSSION 
 
We set out to develop multi-color flow cytometry panels that permit the 
identification of various lymphocyte subsets as well as expression of IL-17A and 
IFNγ after in-vitro stimulation.  We also wanted to interrogate the expression of 4 
KIRs (KIR3DL1, KIR3DS1, KIR2DL5, and KIR3DL2) with the ultimate goal of 
determining whether differential KIR expression correlates with function in HLA-
B27+ versus HLA-B27- subjects. 
 Antibody titration was performed to choose the optimal concentration of 
antibody by comparing the signal strengths of each antibody concentration and 
determining which provided the best signal to background ratio.  Tables 1 and 2 
show the finalized flow panels.  Using 15-color flow cytometry and two panels we 
can distinguish specific lymphocyte subsets including CD4+ T-cells, CD8+ T-
cells, γδ T-cells, NK cells, NK T-cells, and MAIT cells.  In addition, cells 
expressing 4 AS-relevant KIRs (KIR3DL1, KIR3DS1, KIR2DL5, and KIR3DL2) 
can be identified.   
As shown in Figure 11, we were able to determine that NK cells were not 
the only lymphocytes that express KIRs, but that CD4+ and CD8+ T-cells also 
express these KIRs.  Notably, KIR expression was most frequent on NK cells, but 
was still present on both CD4+ and CD8+ T-cells.  Although present on all three 
subsets of lymphocytes, there was substantial variability in the type of KIR 
expressed on each lymphocyte subset and even further variability between 
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samples from different subjects.  This is consistent with Exley’s description of 
KIR expression.22 
 In assembling the three flow cytometry panels, a number of obstacles had 
to be overcome.  First, there was the issue of spectral overlap, which occurs 
when the fluorescence of a particular dye spills into more channels than the one 
that is expected to detect the dye’s fluorescence.42  We were able to account for 
this problem by applying compensation in our analysis to ensure that the 
fluorescent signal detected by each channel came from the fluorophore that was 
getting measured and corrected any potential false positive signal caused by 
spillover.  Second, we observed a downregulation of CD4 upon PMA/Ionomycin 
stimulation as previously described.45  This made it impossible to distinguish the 
CD4+ population during FACS analysis using the initial choice of anti-CD4 
antibody (Anti-CD4 BV510).  We solved this issue by using high concentrations 
of an anti-CD4 FITC antibody to overcome signal loss caused by CD4 
downregulation.  Third, we attempted to use a commercial antibody specific for 
KIR3DL2, but the antibody failed to give off any fluorescent signal.  At this time, 
the number of commercially available antibodies specific to individual KIRs is 
limited, so we had to resort to combinatorial staining strategies.  By gating for the 
KIR3DL1 single marker and the KIR3DL1/DL2 combination marker, we were able 
to identify two different populations of cells.  One of these populations was 
KIR3DL1 and KIR3DL2 double positive and the other population was positive for 
only KIR3DL2 as shown in Figure 10.  Although we did not have a KIR3DL2 
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specific antibody, by using this combinatorial staining strategy, we were able to 
identify a KIR3DL2+ population.   As a wider array of reagents becomes 
commercially available, the analysis of specific KIRs on lymphocyte subsets will 
become more refined.   
Having the multicolor flow cytometry panels described in this thesis 
available, the next steps would be to analyze PBMC samples from HLA-B27+ 
and HLA-27- subjects.  Such a study should include healthy male and female 
subjects age 18-65.  For every HLA-B27 positive subject, an age and sex-
matched HLA-B27 negative control would be identified.  Exclusion criteria for the 
samples would include any diagnosis or history of ankylosing spondylitis, 
spondyloarthritis, psoriasis, psoriatic arthritis, inflammatory bowel disease, 
uveitis, HIV infection, and other autoimmune diseases.  The goal of the 
experiment would be to identify how the KIR repertoire on lymphocyte subsets 
differs between HLA-B27+ and HLA-B27- individuals, and to determine if there is 
a difference in the function (IL-17A secretion) of these different lymphocyte 
subsets.  The testable hypothesis in this experiment would be that lymphocytes 
in HLA-B27 positive subjects, expressing KIR3DL1, KIR3DL2, KIR2DL5, or 
KIR3DS1, differentially produce IL-17A compared with lymphocytes not 
expressing these KIRs.   
Studies in healthy individuals would be followed by the analysis of PBMC 
specimens from patients with AS.  It is feasible that abnormalities in KIR 
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expression lymphocyte subsets may only become apparent in HLA-B27 positive 
individuals after the onset of disease. 
 One potential caveat with regards to the analysis of peripheral blood is 
that PBMCs may behave differently than tissue resident immune cells specific to 
each type of tissue.  However, biopsy specimens from the spine of patients with 
AS are extremely difficult to obtain.  Another consideration is that although 
stimulation with PMA/Io mimics TCR activation, in vivo stimulation may lead to 
different outcomes.   
In conclusion, the work presented in this thesis provides the foundation to 
analyze the expression of AS-relevant KIRs on a variety of lymphocyte subsets 
and the relationship between KIR and IL-17A expression in both HLA-B27+/HLA-
B27- healthy subjects and AS patients.  Understanding how KIR expression 
modulates the production of IL-17A in HLA-B27+ and HLA-B27- subjects will 
deepen the understanding of AS pathogenesis and may contribute to the 
development of curative or preventative interventions in AS.   
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